| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Rita Ferreira | Q64854955 |
| P2093 | author name string | Ross D Hannan | |
| John S Schneekloth | |||
| Katherine M Hannan | |||
| Konstantin I Panov | |||
| P2860 | cites work | The Hallmarks of Cancer | Q221226 |
| Growth factor signaling regulates elongation of RNA polymerase I transcription in mammals via UBF phosphorylation and r-chromatin remodeling | Q42804681 | ||
| Targeting RNA-Polymerase I in Both Chemosensitive and Chemoresistant Populations in Epithelial Ovarian Cancer | Q45064784 | ||
| Targeting RNA polymerase I with an oral small molecule CX-5461 inhibits ribosomal RNA synthesis and solid tumor growth. | Q45995796 | ||
| Modifications of actinomycin D structure as example of actinomycins structure-activity relationship | Q46581443 | ||
| Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma | Q46752273 | ||
| The Dual Inhibition of RNA Pol I Transcription and PIM Kinase as a New Therapeutic Approach to Treat Advanced Prostate Cancer | Q46852163 | ||
| BET Proteins as Targets for Anticancer Treatment | Q47269674 | ||
| c-MYC G-quadruplex binding by the RNA polymerase I inhibitor BMH-21 and analogues revealed by a combined NMR and biochemical Approach. | Q47305788 | ||
| Topoisomerases as anticancer targets | Q49832269 | ||
| The Expanding World of N-MYC-Driven Tumors | Q49873357 | ||
| Tumour heterogeneity and resistance to cancer therapies | Q50112440 | ||
| CDK9 inhibitors in acute myeloid leukemia | Q50318294 | ||
| Ribosome Levels Selectively Regulate Translation and Lineage Commitment in Human Hematopoiesis. | Q51738814 | ||
| Ribosomal DNA copy loss and repeat instability in ATRX-mutated cancers. | Q52579677 | ||
| Small-Molecule Targeting of RNA Polymerase I Activates a Conserved Transcription Elongation Checkpoint. | Q52593929 | ||
| Mutant ATRX: uncovering a new therapeutic target for glioma. | Q55456861 | ||
| Direct relationship between the level of p53 stabilization induced by rRNA synthesis-inhibiting drugs and the cell ribosome biogenesis rate | Q56966045 | ||
| Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries | Q60142201 | ||
| Changes in long-range rDNA-genomic interactions associate with altered RNA polymerase II gene programs during malignant transformation | Q61443253 | ||
| Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs | Q64241956 | ||
| Inhibition of RNA synthesis by actinomycin D: Characteristic dose-response of different RNA species | Q71647340 | ||
| Cisplatin-DNA adducts inhibit ribosomal RNA synthesis by hijacking the transcription factor human upstream binding factor | Q77569614 | ||
| New Roles for the Nucleolus in Health and Disease | Q88230604 | ||
| First-in-Human RNA Polymerase I Transcription Inhibitor CX-5461 in Patients with Advanced Hematologic Cancers: Results of a Phase I Dose-Escalation Study | Q92048436 | ||
| Down-regulation of MYCN protein by CX-5461 leads to neuroblastoma tumor growth suppression | Q92419152 | ||
| Hallmarks of Cancer: The Next Generation | Q22252312 | ||
| Directed proteomic analysis of the human nucleolus | Q24292165 | ||
| Nucleolar transcription factor hUBF contains a DNA-binding motif with homology to HMG proteins | Q24307868 | ||
| Functional proteomic analysis of human nucleolus | Q24318249 | ||
| hRRN3 is essential in the SL1-mediated recruitment of RNA Polymerase I to rRNA gene promoters | Q24545682 | ||
| Actinomycin and DNA transcription | Q24612517 | ||
| The RNA polymerase I transcription machinery | Q24630907 | ||
| Genomic targets of the human c-Myc protein | Q24672480 | ||
| G-quadruplexes and their regulatory roles in biology | Q26782619 | ||
| Basic mechanisms in RNA polymerase I transcription of the ribosomal RNA genes | Q26852331 | ||
| Identification of novel p53 pathway activating small-molecule compounds reveals unexpected similarities with known therapeutic agents | Q27318801 | ||
| Protein synthesis. Rqc2p and 60S ribosomal subunits mediate mRNA-independent elongation of nascent chains | Q27933843 | ||
| ATRX interacts with H3.3 in maintaining telomere structural integrity in pluripotent embryonic stem cells | Q28114801 | ||
| 5-Fluorouracil: mechanisms of action and clinical strategies | Q28201937 | ||
| An immediate response of ribosomal transcription to growth factor stimulation in mammals is mediated by ERK phosphorylation of UBF | Q28210345 | ||
| Mitomycin C: small, fast and deadly (but very selective) | Q28255522 | ||
| c-Myc is a universal amplifier of expressed genes in lymphocytes and embryonic stem cells | Q28275988 | ||
| DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors | Q28303693 | ||
| RNA-binding protein nucleolin in disease | Q28390879 | ||
| Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling | Q28468631 | ||
| Association of DNA topoisomerase I and RNA polymerase I: a possible role for topoisomerase I in ribosomal gene transcription | Q28570763 | ||
| Affinity purification of mammalian RNA polymerase I. Identification of an associated kinase | Q28572297 | ||
| UBF levels determine the number of active ribosomal RNA genes in mammals | Q28585859 | ||
| Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53 | Q28589774 | ||
| The TATA-binding protein and associated factors are integral components of the RNA polymerase I transcription factor, SL1 | Q28611539 | ||
| Cancer. Addiction to oncogenes--the Achilles heal of cancer | Q29614243 | ||
| Cisplatin: mode of cytotoxic action and molecular basis of resistance | Q29615385 | ||
| Pre-ribosomes on the road from the nucleolus to the cytoplasm | Q29616319 | ||
| Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression | Q29617473 | ||
| Tumour heterogeneity and cancer cell plasticity | Q29617990 | ||
| Genetic requirement for Mycl and efficacy of RNA Pol I inhibition in mouse models of small cell lung cancer | Q30276619 | ||
| Stabilization of type I topoisomerase-DNA covalent complexes by actinomycin D | Q33555997 | ||
| Haematopoietic stem cells require a highly regulated protein synthesis rate | Q33588717 | ||
| Inhibition of Pol I transcription treats murine and human AML by targeting the leukemia-initiating cell population | Q33731216 | ||
| Sequence specificity of DNA topoisomerase I in the presence and absence of camptothecin | Q33929257 | ||
| The role of UBF in regulating the structure and dynamics of transcriptionally active rDNA chromatin | Q34019160 | ||
| Nucleolin: dual roles in rDNA chromatin transcription | Q34042024 | ||
| A novel role for the Pol I transcription factor UBTF in maintaining genome stability through the regulation of highly transcribed Pol II genes | Q34042569 | ||
| Cisplatin in cancer therapy: molecular mechanisms of action | Q34098163 | ||
| Alternative lengthening of telomeres: models, mechanisms and implications | Q34107386 | ||
| Targeting G-quadruplexes in gene promoters: a novel anticancer strategy? | Q34174883 | ||
| Nucleolar stress with and without p53. | Q34183329 | ||
| Disruption of the nucleolus mediates stabilization of p53 in response to DNA damage and other stresses | Q34275810 | ||
| Transcriptional amplification in tumor cells with elevated c-Myc. | Q34302542 | ||
| Cancer heterogeneity: implications for targeted therapeutics | Q34321565 | ||
| TBP-TAF complex SL1 directs RNA polymerase I pre-initiation complex formation and stabilizes upstream binding factor at the rDNA promoter. | Q34428135 | ||
| The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy | Q34451477 | ||
| Interactions of actinomycin D with human telomeric G-quadruplex DNA. | Q34495859 | ||
| The transcriptional repressor JHDM3A demethylates trimethyl histone H3 lysine 9 and lysine 36. | Q34531694 | ||
| The RNA polymerase I transcription machinery: an emerging target for the treatment of cancer | Q34615483 | ||
| In vivo sequencing of camptothecin-induced topoisomerase I cleavage sites in human colon carcinoma cells | Q34639985 | ||
| c-MYC coordinately regulates ribosomal gene chromatin remodeling and Pol I availability during granulocyte differentiation | Q34865252 | ||
| UBF activates RNA polymerase I transcription by stimulating promoter escape. | Q34870935 | ||
| Ellipticine cytotoxicity to cancer cell lines - a comparative study | Q35092039 | ||
| Expression analysis with oligonucleotide microarrays reveals that MYC regulates genes involved in growth, cell cycle, signaling, and adhesion | Q35107957 | ||
| Downregulation of rRNA transcription triggers cell differentiation | Q35176898 | ||
| Cardiac hypertrophy: a matter of translation. | Q35188532 | ||
| Selective inhibition of rDNA transcription by a small-molecule peptide that targets the interface between RNA polymerase I and Rrn3. | Q35208439 | ||
| Small molecule BMH-compounds that inhibit RNA polymerase I and cause nucleolar stress. | Q35296557 | ||
| Nucleolar function and size in cancer cells | Q35765408 | ||
| Genome wide mapping of UBF binding-sites in mouse and human cell lines | Q35814075 | ||
| Depletion of the cisplatin targeted HMGB-box factor UBF selectively induces p53-independent apoptotic death in transformed cells. | Q36413821 | ||
| Histone demethylase JMJD2A drives prostate tumorigenesis through transcription factor ETV1. | Q36515134 | ||
| Repair of topoisomerase I-mediated DNA damage | Q36557533 | ||
| Nucleosome binding by the polymerase I transactivator upstream binding factor displaces linker histone H1. | Q36573052 | ||
| The Myc oncoprotein as a therapeutic target for human cancer | Q36578165 | ||
| A liaison between mTOR signaling, ribosome biogenesis and cancer | Q36615429 | ||
| Old drug, new target: ellipticines selectively inhibit RNA polymerase I transcription | Q36620686 | ||
| Cell cycle-dependent regulation of RNA polymerase I transcription: the nucleolar transcription factor UBF is inactive in mitosis and early G1. | Q37197152 | ||
| Nucleolus, ribosomes, and cancer | Q37201211 | ||
| Myc's broad reach | Q37299032 | ||
| MAD1 and c-MYC regulate UBF and rDNA transcription during granulocyte differentiation | Q37485846 | ||
| The histone demethylase JMJD2A/KDM4A links ribosomal RNA transcription to nutrients and growth factors availability. | Q37505139 | ||
| CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours | Q37660623 | ||
| MYC regulation of cell growth through control of transcription by RNA polymerases I and III. | Q37717932 | ||
| MYC as a regulator of ribosome biogenesis and protein synthesis | Q37718002 | ||
| Homologous recombination in cancer development, treatment and development of drug resistance. | Q37721025 | ||
| Dysregulation of the basal RNA polymerase transcription apparatus in cancer | Q38101203 | ||
| The nucleolus: an emerging target for cancer therapy | Q38129532 | ||
| Targeting the nucleolus for cancer-specific activation of p53. | Q38133111 | ||
| Characterization of nucleophosmin (B23) as a Myc target by scanning chromatin immunoprecipitation | Q38295703 | ||
| The role of the histone demethylase KDM4A in cancer. | Q38336938 | ||
| Novel molecular mechanism for actinomycin D activity as an oncogenic promoter G-quadruplex binder | Q38353496 | ||
| A unique enhancer boundary complex on the mouse ribosomal RNA genes persists after loss of Rrn3 or UBF and the inactivation of RNA polymerase I transcription | Q38429843 | ||
| RNA Polymerase I Inhibition with CX-5461 as a Novel Therapeutic Strategy to Target MYC in Multiple Myeloma. | Q38709232 | ||
| A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress | Q38713515 | ||
| rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis | Q38865399 | ||
| Roles of eukaryotic topoisomerases in transcription, replication and genomic stability | Q38959828 | ||
| Dysregulation of histone methyltransferases in breast cancer - Opportunities for new targeted therapies? | Q38975402 | ||
| Selective inhibition of rRNA transcription downregulates E2F-1: a new p53-independent mechanism linking cell growth to cell proliferation. | Q39482087 | ||
| Topoisomerase IIα promotes activation of RNA polymerase I transcription by facilitating pre-initiation complex formation. | Q39554129 | ||
| Chemotherapeutic drugs inhibit ribosome biogenesis at various levels | Q39738796 | ||
| Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis | Q39802021 | ||
| c-Myc associates with ribosomal DNA and activates RNA polymerase I transcription. | Q40456137 | ||
| Interaction of nucleolin with ribosomal RNA genes and its role in RNA polymerase I transcription | Q42408640 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P577 | publication date | 2020-01-21 | |
| P1433 | published in | Cells | Q27724621 |
| P1476 | title | Targeting the RNA Polymerase I Transcription for Cancer Therapy Comes of Age | |
| P478 | volume | 9 |
| Q99571636 | Dysregulated Ribosome Biogenesis Reveals Therapeutic Liabilities in Cancer | cites work | P2860 |
Search more.